Background: Effective HIV treatment with antiretroviral therapy has prolonged sur-
| INTRODUCTION
Aberrant coagulation is a well-described consequence of HIV infection. 1 Deficiencies in key anticoagulants such as protein C (PC) 2, 3 and antithrombin (AT) 4 have been detected in HIV-infected patients, and risk for thromboembolic disease may increase at lower CD4+ counts. 4 With the development and use of effective antiretroviral therapy (ART), morbidity and mortality have been reduced among HIV-infected populations. However, rates of non-AIDS defining conditions, such as cardiovascular disease, have been increasing. 5 Increases in many chronic diseases would be expected with prolonged life expectancy, 6 but a key factor contributing to excess rates of non-AIDS events among treated HIV+ patients includes persistent abnormalities in systemic inflammation and coagulation activity. [7] [8] [9] Higher levels of biomarkers such as d-dimer and interleukin-6 (IL-6) 8-10 among HIV+ patients have been shown to be positively associated with anemia, 11 cancer, 12 cardiovascular disease, 10 type 2 diabetes, 13 progression to AIDS, 14 and composite non-AIDS related clinical events and all-cause mortality. 7, 8, 15 However, a mechanistic basis for the connection between HIV-associated alterations in coagulation activity and risk for a broad spectrum of non-AIDS defining
diseases has yet to be elucidated.
Qualitative or quantitative alterations in the proteins and cells responsible for maintaining the hemostatic balance can result in morbidity and mortality. 16, 17 At the center of many hemostatic processes that regulate bleeding and clotting is the generation of thrombin. 18, 19 Thrombin generation is the central event in hemostasis 20 and a culprit in thrombosis, whereby the suppression of thrombin production and/or function has been proven to be an effective anticoagulant therapy. [21] [22] [23] Thrombin generation assays can be used to define an individual's phenotype through the use of the phases of thrombin generation (initiation, propagation, termination) which are governed by the underlying kinetic reactions and can provide descriptors of the coagulation process (eg, rates, levels, and timing of thrombin formation and inhibition). 24 Studies in the healthy population have
shown that thrombin generation dynamics differ largely between individuals, but are relatively stable over time in a given individual, supporting the concept that they may have utility as a phenotypic marker. [25] [26] [27] The mechanism-based bridge between thrombin generation assays and individualized risk prediction is plasma composition-based computational modeling. 28, 29 Recently, computational models that kinetically describe the tissue-factor initiated coagulation process (extrinsic pathway) have been utilized to define an individual's thrombin phenotype based upon their individual plasma composition of pro-and anticoagulant factors. 30 The central idea with this approach is that in any individual, the balance of the procoagulant and anticoagulant factor levels together act to generate a unique coagulation or thrombin phenotype upon a tissue-factor stimulus. We believe that the sum of developmental, environmental, genetic, nutritional, and pharmacological influences are reflected in the protein levels at any given time that specifically alter the synthesis and/or presentation of the proteins and active enzymes. We have described changes in thrombin generation and related these changes to plasma coagulation factor composition in the following groups: genetic bleeding tendencies [30] [31] [32] [33] and clotting tendencies 34, 35 ; women undergoing in vitro fertilization 36 ; chronic obstructive pulmonary disease 37 ; stroke 38 ; rheumatoid arthritis 39 ;
and cardiovascular disease. 40 In all cases, thrombin generation was more pronounced in individuals with procoagulant vs bleeding tendencies. [30] [31] [32] Individuals with acute conditions appeared to have
Results: Levels of antithrombin and PC decreased, while FV and FVIII were higher in cases vs controls. This resulted in a more procoagulant phenotype with increased MaxR, MaxL, and AUC in cases compared to controls (P < 0.05 for all).
Conclusions: Antithrombin, FV, FVIII, and PC were the major contributors to the increased thrombin generation associated with mortality risk. Our results suggest that mortality in HIV is associated with an increase in in silico thrombin generation via altered balance of pro-and anticoagulant factors, likely due to an inflammatory response signal, and resulting coagulopathy.
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Essentials
• Individuals with HIV frequently present with a procoagulant phenotype.
• Thrombin generation was simulated in death cases and matched controls in a HIV cohort.
• Although clot time was unaffected, the cases did produce more thrombin than controls.
• Differences in factors V and VIII, antithrombin, and protein C accounted for this imbalance.
more pronounced thrombin generation than individuals with chronic conditions. 38, 40 Individuals with inflammatory diseases displayed a wide range of thrombin generation. 37, 39 We previously used this approach to study the consequences of HIV viral replication. 41 We found short-term increases in factor (F) VIII and decreases in both AT and PC when HIV replication increased after stopping ART; reciprocal changes occurred after initiating ART.
The protein concentrations for both groups (treated and untreated HIV infection) were within the normal ranges for healthy individuals, however, these differences resulted in significantly increased thrombin generation during untreated HIV infection, which was shown to be reversible with ART treatment. Whether this increased procoagulant potential translates into a higher risk of adverse clinical endpoints is unknown. In this nested case-control study, we report associations between mortality risk and computationally generated thrombin generation among HIV+ patients treated with ART.
| PATIENTS AND ME THODS

| Study population
The study design was a nested case-control study, sampling patients Cases were defined as death from any non-violent cause (n = 114) during follow-up (median 3 years), and were matched with controls based on age, enrollment date, study, and continent (three controls for every one case). Twenty-four controls were omitted due to an insufficient blood sample to measure factor levels; the remainder (n = 318) were included in our analyses. All participants provided written informed consent.
| Measurement of factor levels and other biomarkers
Blood was collected using EDTA (ethylenediaminetetraacetic acid) High-sensitivity C-reactive protein (hsCRP) was measured by ELISA (Siemens Diagnostics, Munich, Germany for SMART and R&D Systems for ESPRIT).
| Computational model of thrombin generation
Mathematical simulations of tissue factor-initiated thrombin generation were produced as previously described. 45 For each individual, . 46 Results for a particular group of individuals are graphically presented as a curve, which represents the mean thrombin concentration at each second of the reaction (± standard error of the mean). In silico thrombin generation from a hypothetical "control" is defined as all factors set at 100% of the mean physiologic concentration for each factor.
To determine which factor(s) were responsible for differences between cases and controls, we used a previously described procedure 39, 40 in which each of the individuals in the mortality group had one of the factor levels sequentially adjusted to the mean of the control group and the reaction rerun with a 5 pmol/L TF stimulus and in silico thrombin outputs recalculated. This process was repeated for each factor (and expanded to multiple factors simultaneously). The impact of a given factor was evaluated by quantifying the differences between various thrombin generation parameters pre-and post-adjustment.
| Statistical methods
We evaluated the effect of variables used to describe the initiation, propagation, and termination phases of thrombin generation, baseline characteristics, and initial protein concentrations on the risk of mortality with conditional logistic regression analyses for matched case-control studies. Odds ratios (OR) for mortality per 1 log 2 increase in factor levels and modeling parameters are cited. A 1 log 2 increase corresponds to a two times higher factor level or modeling parameter. To assess whether associations between maximum thrombin level and mortality varied by subgroups, an interaction term (product of log 2 level and subgroup indicator) was included in the logistic models. The effect of adjusting for individual factor levels on the maximum level OR for mortality was assessed. 
| RESULTS
| Participant characteristics
| Thrombin generation
The mean thrombin generation (±SEM) for cases and HIV+ controls are shown in Figure 1 were extracted and are presented by group in Table 4 . The OR for mortality risk per log 2 higher level for each thrombin generation parameter is also presented in Table 3 . Although clot time was similar between the two groups, the thrombin generation parameters of MaxR (P = 0.020), MaxL (P = 0.012), and AUC (P = 0.006) were significantly associated with increased mortality risk.
The association of thrombin generation was further evaluated by subgroups defined by traditional risk factors, with data for mortality risk by maximum thrombin levels presented in Table 5 . There was no evidence of a significant interaction of subgroup by higher maximum thrombin level for mortality risk.
Cause of death ESPRIT, n (%) SMART, n (%) Total, n (%) 
| Factor contribution to thrombin generation
In order to determine which factors were responsible for the altered thrombin generation between cases and controls, each of the cases had their thrombin generation curves re-simulated with each factor level set to the median value of the corresponding factor concentration observed in the HIV control cohort. The protein with the largest impact using this methodology was AT. Figure 2A shows the disappearance of differences in simulated thrombin generation between the groups when the cases had their AT set to the median value for controls of 130% (with all other factor levels for cases left unchanged). Figure 2B shows a similar diminishing of thrombin generation differences was seen when a combination of both FV and FVIII in cases were altered to the median values in the controls (111% and 147%, respectively).
This modeling approach was recapitulated with conditional logistic regression. The association between mortality and MaxL of thrombin generation was adjusted for each of the individual factors separately, and the OR for mortality associated with a doubling of MaxL was determined (Table 6 ). Individual adjustment for FV, FVIII, AT, or PC demonstrated the largest attenuation in the association between mortality and MaxL. In addition, adjustment of FV and FVIII together had the most substantial impact on attenuating the association with mortality.
| DISCUSSION
We present data demonstrating for the first time that risk for allcause mortality among HIV+ patients receiving continuous ART is associated with a factor compositional imbalance that corresponds to an increase in simulated thrombin generation. Mortality was associated with increased inflammation, d-dimer, and an altered pro-and anticoagulant balance with higher levels of FV and FVIII and lower levels of PC and AT, yielding a higher procoagulant state among cases of non-violent mortality when compared with controls. These findings expand our understanding of HIV-associated abnormalities in coagulation biology and the consequences for mortality from a broad spectrum of disease, both CVD and non-CVD related.
We have shown in previous analyses of different pathologic states that normal range variation in coagulation factor composition can modulate the relative severity of the thrombin generation defect. 30, 47 The balance between these procoagulant and anticoagulant processes provides a defense against excessive fluid loss (hemorrhage) and against inappropriate vascular occlusion (thrombosis). Previous studies have shown that in HIV+ patients, there exists lower PC and protein S and elevated d-dimer and von Willebrand factor compared to HIV-controls. 48 Higher fibrinogen has also been identified in HIV+ patients. 49 We have also shown from the SMART study that increased HIV replication after stopping ART correlated with increased levels of FVIII and decreased levels of AT and PC, resulting in increased thrombin generation in this computational model. 41 In this current study, both groups of ART-treated HIV+ patients had higher average AT than the mean physiologic population. This finding is in agreement with Hsue et al, 50 who also found higher AT levels in HIV patients (both untreated and those receiving ART) compared to uninfected controls. That study found the higher AT levels contributing to a relatively decreased thrombotic state. In contrast, our HIV+ cohort had a significantly higher prothrombotic We have previously reported that risk for all-cause mortality, as well as a composite of serious non-AIDS defining conditions, is associated with increased levels of d-dimer, a known marker for thrombosis, as well as the inflammatory cytokine IL-6. 7 d-dimer has also been shown to be a predictor of mortality in cancer, 58, 59 acute pulmonary embolism, 60 and (along with CRP) in acute aortic dissection. 61 In this study, mortality risk was associated with parameters of thrombin generation along with differences in the individual factors FV, FVIIII, AT, and PC. Our findings build on our previous work 41 demonstrating that decreased AT and increased FVIII were the primary proteins responsible for the increased thrombin generation associated with HIV viral replication. Here, we show associations between mortality and estimated thrombin generation among ART-treated HIV+ patients that is, in part, accounted for by this same pattern of lower AT and higher FVIII levels. Cumulatively, these data are consistent with our overall hypothesis that HIV-related coagulation abnormalities improve but may persist while on ART, have consequences for a broad spectrum of end-organ disease risk, and may be mediated, at least ). The heterologous presence of any of these circumstances in any individual may still be asymptomatic and does not ordinarily necessitate clinical intervention. In HIV+ patients, ART reduces but does not appear to fully normalize abnormalities in coagulation activation. In this study, all HIV+ patients were on ART therapy, and we show that that residual abnormalities in coagulation factor composition (FV, FVIII, PC, AT), in part, resulting from ongoing inflammation (eg, reflected in IL-6 levels), promote FXa activity which can become an important contributor to the excess thrombin generation observed among mortality cases. Having predictive models that evaluate each individual's specific blood coagulation profile may better inform mortality risk, and help identify potential treatment interventions, among ART-treated HIV+ persons.
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